Immunoenhancer as well as application thereof in vaccine preparation

Abstract

The invention adopts a monoclonal antibody 5D9 with neutralization activity to both PRRSV-I and PRRSV-II viruses to prepare an immunoenhancer. When a formed immune complex is combined with an adjuvantto immunize mice, T cells secreted by IFN-gamma are significantly increased, suggesting that combined immunization of the PRRSV specific antibody 5D9 and the normal oil in water adjuvant can enhanceCTL reaction in the process of inactivating virus immunity. Animal tests show that the immune protection rate of the immune complex prepared by the method can achieve a higher protection effect than that of a vaccine and a commercialized attenuated vaccine prepared only with a commercial adjuvant ISA 206.

Description

Technical field:

[0001] The invention belongs to the field of biology, and in particular relates to an immune enhancer and its application in vaccine preparation, which can be used in the development of therapeutic drugs for porcine reproductive and respiratory syndrome. Background technique:

[0002] Vaccines can be mainly divided into live attenuated vaccines, inactivated vaccines and protein subunit vaccines expressed by genetic engineering techniques. Among the above three types of vaccines, inactivated vaccines and protein subunit vaccines are the most safe, but because they cannot proliferate after being immunized into the body, it is difficult to effectively stimulate the host immune system, often requiring multiple immunizations, and stimulating the body's production of The immune response is mainly based on the humoral immune response (antibody), and it is difficult to stimulate the body to produce a cellular immune response (killer T cells, CTL). Therefore, for som...

Images